Involvement of Nervous System in Muscle Weakness in COPD Patients (DesCoM-1)

This study is currently recruiting participants.
Verified September 2012 by Groupe Fontalvie
Sponsor:
Collaborators:
M2H laboratory, Montpellier University
ANRT, National French Agency for Technological Researches
Information provided by (Responsible Party):
Groupe Fontalvie
ClinicalTrials.gov Identifier:
NCT01679782
First received: September 3, 2012
Last updated: NA
Last verified: September 2012
History: No changes posted

September 3, 2012
September 3, 2012
July 2012
July 2013   (final data collection date for primary outcome measure)
Not Provided
Not Provided
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
Involvement of Nervous System in Muscle Weakness in COPD Patients
Phase 1 Impact of Nocturnal Desaturations on Central Motor Drive in COPD Patients: A New Insight on the Systemic Effects of the Disease.

The purpose of this study is to determine whether nervous system alterations and motor drive failure can contribute to muscle weakness in COPD during voluntary movement. If necessary, we will look after the role of nocturnal hypoxia in these alterations.

COPD is a common disease that induces many systemic repercussions. Among these, peripheral muscle dysfunction is particularly deleterious because it leads to the decreases of the level of activity and the quality of life for patients. Movement involves activation of many structures, from the instructor, i.e. the brain, to the effector, i.e. the muscle. Netherless, the studies which have described peripheral muscle dysfunction have been focused on the muscle, so they have proposed a reducing vision of the phenomenon. Other studies have reported cerebral alterations in COPD, like cognitive disturbance, increase of the neuronal conduction time, and decrease of the white matter density, and were associated with chronic hypoxemia. Such alterations are consistent with the existence of a decrease of the central motor drive during voluntary movement in COPD patients. Therefore the study will aim to determine precisely which mechanisms are involved in peripheral muscle dysfunction in copd.

Observational
Observational Model: Case Control
Time Perspective: Cross-Sectional
Not Provided
Retention:   Samples Without DNA
Description:

whole blood

Non-Probability Sample

Two groups of COPD patients and one group with healthy sedentary subjects

Chronic Obstructive Pulmonary Disease
Not Provided
  • COPD nocturnal desaturator
    COPD patients who spend 30% of the nigth with a SaO2 < 90%.
  • COPD no nocturnal desaturator
    COPD patients who spend less than 30% of the night with a SaO2 < 90%
  • control group
    healthy sedentary subjects
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
45
July 2013
July 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • COPD Patients at stage 2 and 3
  • Healthy sedentary subjects

Exclusion Criteria:

  • Epilepsy, pace-maker, nervous disorders
Both
40 Years to 75 Years
Yes
Contact: Francois FA Alexandre, PhD student 0666678916 ext 0033 francois.alexandre@fontalvie.fr
Contact: Alain AV Varray, Pr 0411759070 ext 0033 alain.varray@univ-montp1.fr
France
 
NCT01679782
FVIE_FA1
Yes
Groupe Fontalvie
Groupe Fontalvie
  • M2H laboratory, Montpellier University
  • ANRT, National French Agency for Technological Researches
Study Director: Alain AV Varray, Pr M2H laboratory, Montpellier
Groupe Fontalvie
September 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP